Iron levels, genes involved in iron metabolism and antioxidative processes and lung cancer incidence.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
12
04
2018
accepted:
20
11
2018
entrez:
15
1
2019
pubmed:
15
1
2019
medline:
19
9
2019
Statut:
epublish
Résumé
Lung cancer is the most common adult malignancy accounting for the largest proportion of cancer related deaths. Iron (Fe) is an essential trace element and is a component of several major metabolic pathways playing an important role in many physiological processes. In this study we evaluated the association between Fe concentration in serum, iron metabolism parameters and genetic variaton in 7 genes involved in iron metabolism and anti-oxidative processes with the incidence of lung cancer in Poland. The study included 200 lung cancer patients and 200 matched healthy control subjects. We analyzed serum iron concentration and iron metabolism parameters (TIBC, UIBC, serum ferritin and transferrin saturation), and genotyped seven variants in seven genes: HFE, TFR1, HAMP, TF, SOD2, CAT and GPX1. Lung cancer patients compared to their matched controls had significantly higher mean serum iron level (p = 0.01), ferritin level (p = 0.007) and TIBC (p = 0.006). Analysis revealed that higher concentration of iron and ferritin (IVth quartile) compared to the lower concentration (Ist quartile) was associated with over 2-fold increased lung cancer incidence. We also found that higher transferrin saturation (p = 0.01) and lower TIBC (p<0.01) are associated with better survival of lung cancer patients. The analysis of polymorphisms in iron related genes did not reveal a significant difference between lung cancer patients and controls. However, rs10421768 in HAMP showed a borderline statistically significant correlation with lung cancer risk (OR = 2.83, p = 0.05). The results of this case control study indicate that higher body iron represented by higher Fe and ferritin levels may be associated with lung cancer incidence. Rs10421768 in HAMP may be associated with about 3-times higher lung cancer risk. Higher Fe body content may be associated with better survival of lung cancer patients.
Sections du résumé
BACKGROUND
Lung cancer is the most common adult malignancy accounting for the largest proportion of cancer related deaths. Iron (Fe) is an essential trace element and is a component of several major metabolic pathways playing an important role in many physiological processes. In this study we evaluated the association between Fe concentration in serum, iron metabolism parameters and genetic variaton in 7 genes involved in iron metabolism and anti-oxidative processes with the incidence of lung cancer in Poland.
MATERIALS AND METHODS
The study included 200 lung cancer patients and 200 matched healthy control subjects. We analyzed serum iron concentration and iron metabolism parameters (TIBC, UIBC, serum ferritin and transferrin saturation), and genotyped seven variants in seven genes: HFE, TFR1, HAMP, TF, SOD2, CAT and GPX1.
RESULTS
Lung cancer patients compared to their matched controls had significantly higher mean serum iron level (p = 0.01), ferritin level (p = 0.007) and TIBC (p = 0.006). Analysis revealed that higher concentration of iron and ferritin (IVth quartile) compared to the lower concentration (Ist quartile) was associated with over 2-fold increased lung cancer incidence. We also found that higher transferrin saturation (p = 0.01) and lower TIBC (p<0.01) are associated with better survival of lung cancer patients. The analysis of polymorphisms in iron related genes did not reveal a significant difference between lung cancer patients and controls. However, rs10421768 in HAMP showed a borderline statistically significant correlation with lung cancer risk (OR = 2.83, p = 0.05).
CONCLUSIONS
The results of this case control study indicate that higher body iron represented by higher Fe and ferritin levels may be associated with lung cancer incidence. Rs10421768 in HAMP may be associated with about 3-times higher lung cancer risk. Higher Fe body content may be associated with better survival of lung cancer patients.
Identifiants
pubmed: 30640897
doi: 10.1371/journal.pone.0208610
pii: PONE-D-18-11043
pmc: PMC6331102
doi:
Substances chimiques
Antioxidants
0
Iron
E1UOL152H7
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0208610Déclaration de conflit d'intérêts
The authors have read the journal's policy and have the following conflicts: The authors WM, MM, and JL are employed by Read-Gene S.A.; SG is employed by Strand Life Sciences; and PW is employed by an Independent Laboratory of Pathology. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials. There are no patents, products in development or marketed products to declare.
Références
Epidemiology. 2005 Nov;16(6):772-9
pubmed: 16222167
Cancer Res. 2014 Nov 15;74(22):6589-97
pubmed: 25228650
Asian Pac J Cancer Prev. 2010;11(5):1383-8
pubmed: 21198297
Int J Clin Exp Med. 2015 Sep 15;8(9):14647-55
pubmed: 26628947
Cancer. 2001 Jun 15;91(12):2214-21
pubmed: 11413508
Haematologica. 2010 May;95(5):849-50
pubmed: 20007145
Int J Biol Markers. 2006 Oct-Dec;21(4):235-41
pubmed: 17177162
Anal Biochem. 1971 Apr;40(2):450-8
pubmed: 5551554
Clin Chem Lab Med. 2002 Oct;40(10):1014-8
pubmed: 12476940
J Thorac Oncol. 2006 Sep;1(7):648-53
pubmed: 17409931
Cancer Lett. 2007 Mar 18;247(2):293-300
pubmed: 16797832
Tumour Biol. 2014 Oct;35(10):10195-9
pubmed: 25027402
Biochem Genet. 1993 Aug;31(7-8):321-8
pubmed: 8274138
Cancer Sci. 2009 Jan;100(1):9-16
pubmed: 19018762
N Engl J Med. 1988 Oct 20;319(16):1047-52
pubmed: 3173433
J Cancer Res Ther. 2014 Jul-Sep;10(3):681-5
pubmed: 25313760
Int J Cancer. 1994 Feb 1;56(3):364-9
pubmed: 8314323
Cancer Epidemiol Biomarkers Prev. 2003 Oct;12(10):980-6
pubmed: 14578132
Biomed Pharmacother. 2016 May;80:127-135
pubmed: 27133049
Blood Cells Mol Dis. 2015 Jun;55(1):71-5
pubmed: 25976471
Int J Cancer. 1994 Feb 1;56(3):379-82
pubmed: 8314326
Sci Rep. 2017 Aug 21;7(1):8371
pubmed: 28827732
Ann Oncol. 2017 May 1;28(5):1124-1129
pubmed: 28453699
Cancer Cell Int. 2011 Feb 14;11:3
pubmed: 21320311
Br J Nutr. 2017 Feb;117(4):572-581
pubmed: 28382896
Cancer Res. 2000 Nov 15;60(22):6381-3
pubmed: 11103801
Int J Clin Oncol. 2018 Aug;23(4):671-680
pubmed: 29633053
Clin Chem Lab Med. 2008;46(10):1450-7
pubmed: 18844501
Eur J Nutr. 2017 Jun;56(4):1637-1646
pubmed: 27073037
Asian Pac J Cancer Prev. 2015;16(11):4633-9
pubmed: 26107216
Int J Epidemiol. 1995 Aug;24(4):665-70
pubmed: 8550261
J Trace Elem Med Biol. 2007;21 Suppl 1:14-7
pubmed: 18039488
Br J Cancer. 1991 Nov;64(5):895-8
pubmed: 1657106
Anticancer Res. 1991 Nov-Dec;11(6):2107-10
pubmed: 1663720
Eur J Cancer Clin Oncol. 1986 Jul;22(7):831-5
pubmed: 3021467
Am J Clin Nutr. 2009 Jun;89(6):1884-94
pubmed: 19369370
Nutr Cancer. 2005;52(2):130-7
pubmed: 16201844